Last updated on June 2020

Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias or Solid Tumors


Brief description of study

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and efficacy of ponatinib in children aged 1 to < 18 years with advanced leukemias, lymphomas, and solid tumors.

Clinical Study Identifier: NCT03934372

Find a site near you

Start Over

H pital Robert Debr

Paris, France
1.46miles
  Connect »

H pital Robert Debr

Paris, France
1.46miles
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.